Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models

Phytomedicine
2021.0

Abstract

BACKGROUND: Parkinson's disease (PD) is one of the most common neurodegenerative motor disorders, and is characterized by the presence of Lewy bodies containing misfolded alpha-synuclein (alpha-syn) and by selective degeneration of midbrain dopamine neurons. Studies have shown that upregulation of ubiquitin-proteasome system (UPS) activity promotes the clearance of aggregation-prone proteins such as alpha-syn and Tau, so as to alleviate the neuropathology of neurodegenerative diseases. PURPOSE: To identify and investigate lycorine as a UPS enhancer able to decrease alpha-syn in transgenic PD models. METHODS: Dot blot was used to screen alpha-syn-lowering compounds in an inducible alpha-syn overexpression cell model. Inducible wild-type (WT) and mutant alpha-syn-overexpressing PC12 cells, WT alpha-syn-overexpressing N2a cells and primary cultured neurons from A53T transgenic mice were used to evaluate the effects of lycorine on alpha-syn degradation in vitro. Heterozygous A53T transgenic mice were used to evaluate the effects of lycorine on alpha-syn degradation in vivo. mCherry-GFP-LC3 reporter was used to detect autophagy-dependent degradation. Ub-R-GFP and Ub-G76V-GFP reporters were used to detect UPS-dependent degradation. Proteasome activity was detected by fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC). RESULTS: Lycorine significantly promoted clearance of over-expressed WT and mutant alpha-syn in neuronal cell lines and primary cultured neurons. More importantly, 15 days' intraperitoneal administration of lycorine effectively promoted the degradation of alpha-syn in the brains of A53T transgenic mice. Mechanistically, lycorine accelerated alpha-syn degradation by activating cAMP-dependent protein kinase (PKA) to promote proteasome activity. CONCLUSION: Lycorine is a novel alpha-syn-lowering compound that works through PKA-mediated UPS activation. This ability to lower alpha-syn implies that lycorine has the potential to be developed as a pharmaceutical for the treatment of neurodegenerative diseases, such as PD, associated with UPS impairment and protein aggregations. CI - Copyright (c) 2021. Published by Elsevier GmbH.

Knowledge Graph

Similar Paper

Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models
Phytomedicine 2021.0
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway
npj Parkinson's Disease 2022.0
Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of α-Synucleinopathies
Journal of Medicinal Chemistry 2022.0
Discovery of 3-Arylcoumarin-tetracyclic Tacrine Hybrids as Multifunctional Agents against Parkinson’s Disease
ACS Medicinal Chemistry Letters 2014.0
Corynoxine B targets at HMGB1/2 to enhance autophagy for α-synuclein clearance in fly and rodent models of Parkinson's disease
Acta Pharmaceutica Sinica B 2023.0
Corynoxine Protects Dopaminergic Neurons Through Inducing Autophagy and Diminishing Neuroinflammation in Rotenone-Induced Animal Models of Parkinson’s Disease
Frontiers in Pharmacology 2021.0
Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease
International Journal of Molecular Sciences 2020.0
Sophora alopecuroides Alleviates Neuroinflammation and Oxidative Damage of Parkinson’s Disease In Vitro and In Vivo
The American Journal of Chinese Medicine 2023.0
Sophora alopecuroides Alleviates Neuroinflammation and Oxidative Damage of Parkinson’s Disease In Vitro and In Vivo
An Overview of Traditional Chinese Medicine Research 2024.0
A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson’s Disease
Journal of Medicinal Chemistry 2021.0